RESEARCH PAPER
Plasma and semen viral loads discordance in HIV-positive patients receiving antiretroviral treatment (ART) in Tehran: an implication for a healthy pregnancy
1
Iranian Research Center for HIV/AIDS, Iranian Institute for Reduction of High-Risk Behaviors, Tehran University of Medical Sciences, Tehran, Iran
2
Department of Microbiology, Faculty of Medicine, Aja University of Medical Sciences, Tehran, Iran
3
Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway
Submission date: 2021-01-03
Final revision date: 2021-04-07
Acceptance date: 2021-04-08
Publication date: 2022-10-07
HIV & AIDS Review 2022;21(4):301-304
KEYWORDS
TOPICS
ABSTRACT
Introduction:
In human immunodeficiency virus (HIV)-positive patients, viral load replication in blood plasma (BP) and genital fluid, such as semen plasma (SP), are different. Several factors, including HIV concentration in semen, virus infectiousness, and susceptibility of host cells determine the risk of transmission from HIV male patients to their sexual partners. Previous studies had controversial results on the correlation of BP viral load and SP viral load and the impact of antiretroviral therapy (ART) on BP and SP viral load. The aim of the study was to evaluate the impact of different ART regimens on BP and SP viral loads.
Material and methods:
Nineteen HIV-positive male patients, with a mean age of 35.8 years, were included in the study, each of whom had been receiving various ART regimen for at least six months. Both whole blood and semen samples were collected on the same day and subsequently, HIV-1 RNA copy was measured in both samples for each patient.
Results:
Our results indicated that in patients who were at least six months under ART regimen, mean HIV RNA copy number in BP and SP were 1,371 copy/ml and 273 copy/ml, respectively. Our results demonstrated a significantly higher BP viral load level than SP viral load (p = 0.001). Moreover, a significant correlation between BP viral load and SP viral load was observed (Pearson correlation = 0.97).
Conclusions:
We conclude that SP viral load of HIV-positive patients with undetectable BP viral load was below detection range. This point should be communicated to sero-discordant couples who want to have a safe pregnancy and healthy offspring.
In human immunodeficiency virus (HIV)-positive patients, viral load replication in blood plasma (BP) and genital fluid, such as semen plasma (SP), are different. Several factors, including HIV concentration in semen, virus infectiousness, and susceptibility of host cells determine the risk of transmission from HIV male patients to their sexual partners. Previous studies had controversial results on the correlation of BP viral load and SP viral load and the impact of antiretroviral therapy (ART) on BP and SP viral load. The aim of the study was to evaluate the impact of different ART regimens on BP and SP viral loads.
Material and methods:
Nineteen HIV-positive male patients, with a mean age of 35.8 years, were included in the study, each of whom had been receiving various ART regimen for at least six months. Both whole blood and semen samples were collected on the same day and subsequently, HIV-1 RNA copy was measured in both samples for each patient.
Results:
Our results indicated that in patients who were at least six months under ART regimen, mean HIV RNA copy number in BP and SP were 1,371 copy/ml and 273 copy/ml, respectively. Our results demonstrated a significantly higher BP viral load level than SP viral load (p = 0.001). Moreover, a significant correlation between BP viral load and SP viral load was observed (Pearson correlation = 0.97).
Conclusions:
We conclude that SP viral load of HIV-positive patients with undetectable BP viral load was below detection range. This point should be communicated to sero-discordant couples who want to have a safe pregnancy and healthy offspring.
REFERENCES (40)
1.
Kalichman SC, Di Berto G, Eaton L. Human immunodeficiency virus viral load in blood plasma and semen: review and implications of empirical findings. Sex Transm Dis 2008; 35: 55-60.
2.
SeyedAlinaghi S, Taj L, Mazaheri-Tehrani E, et al. HIV in Iran: onset, responses and future directions. AIDS 2021; 35: 529-542.
3.
Mehraeen E, Safdari R, SeyedAlinaghi SA, Mohammadzadeh N. Exploring and prioritization of mobile-based self-management strategies for HIV care. Infect Disord Drug Targets 2019; 19: 288-296.
4.
Mehraeen E, Safdari R, Seyedalinaghi SA, Mohammadzadeh N, Arji G. Identifying and validating requirements of a mobile-based self-management system for people living with HIV. Stud Health Technol Inform 2018; 248: 140-147.
5.
Jiwatram-Negrón T, El-Bassel N. Systematic review of couple-based HIV intervention and prevention studies: advantages, gaps, and future directions. AIDS Behav 2014; 18: 1864-1887.
6.
Niakan S, Mehraeen E, Noori T, Gozali E. Web and mobile based HIV prevention and intervention programs pros and cons – a review. Stud Health Technol Inform 2017; 236: 319-327.
7.
Chemaitelly H, Cremin I, Shelton J, Hallett TB, Abu-Raddad LJ. Distinct HIV discordancy patterns by epidemic size in stable sexual partnerships in sub-Saharan Africa. Sex Transm Infect 2012; 88: 51-57.
8.
Mehraeen E, Safdari R, Mohammadzadeh N, Seyedalinaghi SA, Forootan S, Mohraz M. Mobile-based applications and functionalities for self-management of people living with HIV. Stud Health Technol Inform 2018; 248: 172-179.
9.
Chemaitelly H, Shelton JD, Hallett TB, Abu-Raddad LJ. Only a fraction of new HIV infections occur within identifiable stable discordant couples in sub-Saharan Africa. AIDS 2013; 27: 251-260.
10.
Dunkle KL, Stephenson R, Karita E, et al. New heterosexually transmitted HIV infections in married or cohabiting couples in urban Zambia and Rwanda: an analysis of survey and clinical data. Lancet 2008; 371: 2183-2191.
11.
Muessig KE, Smith MK, Powers KA, et al. Does ART prevent HIV transmission among MSM? AIDS 2012; 26: 2267-2273.
12.
Du P, Liu A, Jiao Y, et al. HIV RNA and proviral HIV DNA can be detected in semen after 6 months of antiretroviral therapy although HIV RNA is undetectable in blood. Microbiol Immunol 2016; 60: 187-195.
13.
Medeiros RP, Munerato P, Diaz RS. HIV-1 viral load in blood and semen plasma of Brazilian patients under antiretroviral therapy. J Clin Virol 2004; 30: 346-347.
14.
Politch JA, Mayer KH, Welles SL, et al. Highly active antiretroviral therapy does not completely suppress HIV in semen of sexually active HIV-infected men who have sex with men. AIDS 2012; 26: 1535-1543.
15.
Crepaz N, Hart TA, Marks G. Highly active antiretroviral therapy and sexual risk behavior: a meta-analytic review. JAMA 2004; 292: 224-236.
16.
Kalichman SC, Eaton L, Cain D, et al. Changes in HIV treatment beliefs and sexual risk behaviors among gay and bisexual men, 1997-2005. Health Psychol 2007; 26: 650-656.
17.
Moradbeigi M, SeyedAlinaghi S, Sajadipour M, et al. The relationship between HIV antibody titer, HIV viral load, HIV p24 antigen, and CD4 T-cell count among Iranian HIV-positive patients. Infect Disord Drug Targets 2020; 20: 752-757.
18.
Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med 2000; 342: 921-929.
19.
Lowe SH, Wensing AMJ, Droste JAH, et al. No virological failure in semen during properly suppressive antiretroviral therapy despite subtherapeutic local drug concentrations. HIV Clin Trials 2006; 7: 285-290.
20.
Winter AJ, Taylor S, Workman J, et al. Asymptomatic urethritis and detection of HIV-1 RNA in seminal plasma. Sex Transm Infect 1999; 75: 261-263.
21.
Vernazza PL, Troiani L, Flepp MJ, et al. Potent antiretroviral treatment of HIV-infection results in suppression of the seminal shedding of HIV. The Swiss HIV Cohort Study. AIDS 2000; 14: 117-121.
22.
Liuzzi G, Chirianni A, Bagnarelli P, Clementi M, Piazza M. A combination of nucleoside analogues and a protease inhibitor reduces HIV-1 RNA levels in semen: implications for sexual transmission of HIV infection. Antivir Ther 1999; 4: 95-99.
23.
Gupta P, Mellors J, Kingsley L, et al. High viral load in semen of human immunodeficiency virus type 1-infected men at all stages of disease and its reduction by therapy with protease and nonnucleoside reverse transcriptase inhibitors. J Virol 1997; 71: 6271-6275.
24.
Lorello G, la Porte C, Pilon R, Zhang G, Karnauchow T, MacPherson P. Discordance in HIV-1 viral loads and antiretroviral drug concentrations comparing semen and blood plasma. HIV Med 2009; 10: 548-554.
25.
Zhang J, Wang N, He L, Pan X, Ding X. Short communication: Discordance of HIV-1 viral load from paired blood and seminal plasma samples in a Chinese men who have sex with men population. AIDS Res Hum Retroviruses 2019; 35: 393-395.
26.
Eron JJ Jr, Smeaton LM, Fiscus SA, et al. The effects of protease inhibitor therapy on human immunodeficiency virus type 1 levels in semen (AIDS clinical trials group protocol 850). J Infect Dis 2000; 181: 1622-1628.
27.
Bujan L, Daudin M, Matsuda T, et al. Factors of intermittent HIV-1 excretion in semen and efficiency of sperm processing in obtaining spermatozoa without HIV-1 genomes. AIDS 2004; 18: 757-766.
28.
Leruez-Ville M, Dulioust E, Costabliola D, et al. Decrease in HIV-1 seminal shedding in men receiving highly active antiretroviral therapy: an 18 month longitudinal study (ANRS EP012). AIDS 2002; 16: 486-488.
29.
Barroso PF, Schechter M, Gupta P, Bressan C, Bomfim A, Harrison LH. Adherence to antiretroviral therapy and persistence of HIV RNA in semen. J Acquir Immune Defic Syndr 2003; 32: 435-440.
30.
Lafeuillade A, Solas C, Chadapaud S, Hittinger G, Poggi C, Lacarelle B. HIV-1 RNA levels, resistance, and drug diffusion in semen versus blood in patients receiving a lopinavir-containing regimen. J Acquir Immune Defic Syndr 2003; 32: 462-464.
31.
Lafeuillade A, Solas C, Halfon P, Chadapaud S, Hittinger G, Lacarelle B. Differences in the detection of three HIV-1 protease inhibitors in non-blood compartments: clinical correlations. HIV Clin Trials 2002; 3: 27-35.
32.
Sadiq ST, Taylor S, Kaye S, et al. The effects of antiretroviral therapy on HIV-1 RNA loads in seminal plasma in HIV-positive patients with and without urethritis. AIDS 2002; 16: 219-225.
33.
Chan DJ. Pathophysiology of HIV-1 in semen: current evidence for compartmentalisation and penetration by antiretroviral drugs. Curr HIV Res 2005; 3: 207-222.
34.
Vernazza P, Hirschel B, Bernasconi E, Flepp M. HIV-positive individuals without additional sexually transmitted diseases (STD) and on effective antiretroviral therapy are sexually non-infectious. Schweizerische Ärztezeitung 2008; 89: 165-169.
35.
Baesi K, Ravanshad M, Ghanbarisafari M, Saberfar E, Seyedalinaghi S, Volk JE. Antiretroviral drug resistance among antiretroviral-naïve and treatment experienced patients infected with HIV in Iran. J Med Virol 2014; 86: 1093-1098.
36.
Khalili H, Rohani R, Seyedalinaghi S, Hajiabdolbaghi M, Dashti-Khavidaki S, Talasaz AH. Adherence to antiretroviral therapy among Iranian HIV/AIDS patients. Curr Clin Pharmacol 2012; 7: 111-115.
37.
Alinaghi SAS, Rasoolinejad M, Najafi Z, Dadras O, Malekianzadeh E, Mirzazadeh A. Drug resistance patterns in HIV patients with virologic failure in Iran. Arch Clin Infect Dis 2019; 14: e96531.
38.
Mohraz M, Tayeri K, Namdari Tabar H, et al. Evaluation of acquired HIV drug resistance among people living with HIV who have taken antiretroviral therapy for 9-15 months in 14 triangular clinics in Iran, 2015-2016. Intervirology 2018; 61: 292-300.
39.
Koochak HE, Babaii A, Pourdast A, et al. Prevalence of adverse drug reactions to highly active antiretroviral therapy (HAART) among HIV positive patients in Imam Khomeini Hospital of Tehran, Iran. Infect Disord Drug Targets 2017; 17: 116-119.
40.
Baesi K, Moallemi S, Farrokhi M, Alinaghi SA, Truong HM. Subtype classification of Iranian HIV-1 sequences registered in the HIV databases, 2006-2013. PLoS One 2014; 9: e105098.
Share
RELATED ARTICLE
| eISSN: | 1732-2707 |
| ISSN: | 1730-1270 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
